(NASDAQ: PASG) Passage Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.53%.
Passage Bio's earnings in 2026 is -$36,112,000.On average, 5 Wall Street analysts forecast PASG's earnings for 2026 to be -$35,513,038, with the lowest PASG earnings forecast at -$44,400,630, and the highest PASG earnings forecast at -$29,056,824. On average, 5 Wall Street analysts forecast PASG's earnings for 2027 to be -$33,893,836, with the lowest PASG earnings forecast at -$36,422,391, and the highest PASG earnings forecast at -$31,185,406.
In 2028, PASG is forecast to generate -$29,933,356 in earnings, with the lowest earnings forecast at -$29,547,862 and the highest earnings forecast at -$29,969,073.